The Cellix Bio Synergix platform technology utilizes existing knowledge of disease pathophysiology creatively adapts the pharmacologic properties of existing standard-of-care therapies and/or promising disease-modifying agents. This enables us to discover and potentially deliver novel therapies to patients living with serious medical needs in our therapeutic areas of focus.

Cellix Bio innovative platform

an effective methodology to drug design that focuses on creating new molecular entities with improved pharmacokinetic profile and synergistic pharmacology. Synergix aims to target known biomolecular pathophysiological pathways considered likely to yield significant therapeutic benefits and to develop structural molecular chemistries to optimize the Company’s New Molecular Entities (NMEs).

The NMEs are are designed to be cleaved by specific enzymes exclusively within cells or by the mediation of specific intestinal enzymes. This cleavage potentially releases two bioactives independently, which in turn would allow the bioactives to reach their targets more efficiently, with greater efficacy and better PK-PD profile than if the bioactives were dosed independently or in combination.

Cellix Bio’s Synergix platform technology has the capability to deliver both clinical and commercial successes. Our approach is unique and enables important functional capabilities.


Synergix platform


Repurposing established small molecule/biologic drugs for other indications.

Platform Technology

First Cellix Bio identifies and selects a specific therapeutic candidate and its concert bioactive endogenous molecule to treat a particular disease. Then Cellix uses its proprietary platform technology to modulate the biochemical pathway of that disease, with a permissive chemical modification through a linker chemistry. This enables Cellix to create a novel drug candidate with potential for enhanced efficacy, tolerability and safety.

Drug Transformation

We selected established drugs and transform them utilizing long chain fatty acid chemistry to enhance their molecular profile and augment their pharmacological and disease modifying potential.

Through its Synergix platform, Cellix Bio utilizes significant expertise and know-how to unearth diverse pharmacology improvements and reap substantial advantages in the drug development process.

NextGen Framework

Some key benefits are

  • Relatively rapid clinical development
  • Low drug development risk
  • Explicit improvements in patient outcomes
  • Improved value for patients, caregivers and market payers